Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS – Get Rating) was the target of a significant growth in short interest in February. As of February 15th, there was short interest totalling 703,900 shares, a growth of 7.6% from the January 31st total of 654,300 shares. Based on an average daily volume of 910,000 shares, the days-to-cover ratio is currently 0.8 days.
Analysts Set New Price Targets
Several equities analysts have recently commented on the stock. HC Wainwright lowered their target price on shares of Aridis Pharmaceuticals from $19.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday, January 26th. Northland Securities lowered their price objective on shares of Aridis Pharmaceuticals from $5.00 to $2.00 in a research note on Wednesday, November 23rd.
Aridis Pharmaceuticals Stock Performance
ARDS stock opened at $0.52 on Friday. The firm has a market cap of $10.90 million, a price-to-earnings ratio of -0.23 and a beta of 1.07. The firm has a 50-day simple moving average of $0.89 and a two-hundred day simple moving average of $1.07. Aridis Pharmaceuticals has a one year low of $0.48 and a one year high of $2.77.
Hedge Funds Weigh In On Aridis Pharmaceuticals
Aridis Pharmaceuticals Company Profile
Aridis Pharmaceuticals, Inc engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-101, AR-501, AR-712, AR-701, AR-401, AR-105 and AR-201. The company was founded by Eric J.
- Get a free copy of the StockNews.com research report on Aridis Pharmaceuticals (ARDS)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.